Home / Market News / $RHHBY
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Roche Diagnostics Makes Endotrophin Research Prototype Assay Available at Nordic Bioscience

Nov 16, 2026, 1:03 PM UTC · Primary ticker $RHHBY

Roche Diagnostics has made its Endotrophin research prototype assay available at Nordic Bioscience's CLIA-certified lab, enabling research into inflammation, fibrosis, and metabolic, kidney, and cardiovascular diseases. This move expands the accessibility of a new biomarker for research purposes, potentially accelerating drug discovery and diagnostic development in these areas.

Roche Diagnostics has announced the availability of its Endotrophin (ETP) research prototype assay at Nordic Bioscience. This is a significant step as it provides researchers with access to a new biomarker associated with various serious conditions like inflammation, fibrosis, and metabolic, kidney, and cardiovascular diseases. For Roche, this expands the utility and reach of its diagnostic platform (cobas e801) and its ETP assay, potentially leading to future commercialization opportunities if the research proves fruitful. Nordic Bioscience benefits by enhancing its research capabilities and attracting more studies. While not immediately market-moving in terms of revenue, this collaboration represents a long-term opportunity for both companies to contribute to and potentially capitalize on advancements in disease diagnosis and treatment, with the key risk being the success and clinical relevance of the research conducted using the assay.

$RHHBY positive Expanded assay availability
$NBIOD positive Hosting new research assay
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.